Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Frontiers in Genetics|February 28, 2022
Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine PathwaysKubra Karagoz, Matthew Stokes, María Ortiz-Estévez, et al.
Ejhaem|July 18, 2022
Validation of clinical-grade whole genome sequencing reproduces cytogenetic analysis and identifies mutational landscape in newly-diagnosed multiple myeloma patients: A pilot study from the 100,000 Genomes ProjectOliver C Lomas, Sarah Gooding, Maite Cabes, et al.
Plos One|September 15, 2015
Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare CostsSarah Gooding, I-Jun Lau, Mimi Sheikh, et al.
The Journal of Infection|December 26, 2006
Impact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practiceSarah Gooding, Oni Chowdhury, Tim Hinks, et al.
Ejhaem|June 18, 2025
Risk adapted therapy for newly diagnosed multiple myeloma delivered through local cytogenetic laboratories in a National Clinical Trial: UKMRA RADAR studyDipal Mehta, Robert Cicero, Laura Chiecchio, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|January 18, 2025
Quantitative liver function imaging and whole genome sequencing - Effective modalities for a new era in personalised decision-making for operable colorectal liver metastases?Fenella Welsh, Senthil Sundaravadanan, Pulkit Sethi, et al.
Blood|October 12, 2022
Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myelomaNaser Ansari-Pour, Mehmet Samur, Erin Flynt, et al.
Scientific Reports|October 4, 2019
Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironmentSam W Z Olechnowicz, Megan M Weivoda, Seint T Lwin, et al.
Blood|January 14, 2021
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myelomaSarah Gooding, Naser Ansari-Pour, Fadi Towfic, et al.
Cell Reports. Medicine|May 22, 2024
Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myelomaOliver Van Oekelen, Michael Amatangelo, Manman Guo, et al.
Pageof 4